Foghorn Therapeutics
FHTX
65 hedge funds and large institutions have $166M invested in Foghorn Therapeutics in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 23 increasing their positions, 11 reducing their positions, and 8 closing their positions.
3,140% more call options, than puts
Call options by funds: $486K | Put options by funds: $15K
109% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 11
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
5% more funds holding
Funds holding: 62 → 65 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.75% less ownership
Funds ownership: 63.18% → 62.43% (-0.75%)
26% less capital invested
Capital invested by funds: $226M → $166M (-$59.2M)
Top Buyers
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$3.89M |
| 2 |
BlackRock
New York
|
+$1.45M |
| 3 |
RWM
Rockwood Wealth Management
New Hope,
Pennsylvania
|
+$1.14M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
+$829K |
| 5 |
GW
GW & Wade
Wellesley,
Massachusetts
|
+$813K |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$5.54M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.68M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.25M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$322K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$232K |
FHTX Hedge Fund Activity: Q4 2022 in Review
65 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q4 2022, worth a combined $166M — down 26% from $226M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new FHTX positions and 8 closed out — a net gain of 3 holders — while 23 added to existing stakes and 11 trimmed.
The largest buyer was Raymond James & Associates, adding an estimated $3.89M. The largest seller was Morgan Stanley, cutting an estimated $5.54M.
- 65 institutional investors held Foghorn Therapeutics (FHTX) as of Q4 2022, up from 62 in Q3 2022.
- Funds reported $166M of Foghorn Therapeutics stock for Q4 2022, down 26% quarter-over-quarter.
- 11 funds opened new Foghorn Therapeutics positions in Q4 2022 and 8 closed out, a net change of +3 holders.
- The largest Foghorn Therapeutics buyer in Q4 2022 was Raymond James & Associates, an estimated $3.89M added.
- The largest Foghorn Therapeutics seller in Q4 2022 was Morgan Stanley, an estimated $5.54M sold.
Based on aggregated 13F filings for Q4 2022.